Viz.ai, Inc.

https://viz.ai

Viz.ai is a leading artificial intelligence (AI) powered healthcare company focused on improving patient outcomes through accelerated care coordination and clinical workflow solutions. Founded in 2016 by Dr. Chris Mansi and Dr. David Golan, the company's mission is to increase access to life-saving treatments by reducing systemic delays in healthcare. Headquartered in San Francisco, California, Viz.ai leverages advanced technology to transform how medical decisions are made and care is delivered.

The core of Viz.ai's offering is the Viz.ai One platform, which integrates over 50 FDA-cleared AI algorithms to analyze medical imaging data, including CT scans, EKGs, and echocardiograms. This platform provides real-time insights and automated assessments, streamlining diagnosis and treatment pathways. The company offers specialized suites such as Viz Neuro Suite for neurovascular diseases, Viz Vascular Suite for conditions like pulmonary embolism, Viz Cardio Suite for cardiac issues, Viz Trauma Suite, and Viz Radiology Suite. Viz.ai serves a broad market, including hospitals, health systems, and clinical specialists, and also collaborates with pharmaceutical and medical device companies through its Viz Life Sciences division.

Viz.ai has achieved significant market penetration, with its platform deployed in nearly 2,000 hospitals across the United States and Europe, covering over 230 million lives. In March 2024, Michael Herring was appointed as Chief Financial Officer, joining co-founder and CEO Dr. Chris Mansi in leadership. The company has seen substantial growth, doubling its life sciences business with 13 strategic partnerships, and achieved profitability in its healthcare business in 2025. Viz.ai has been recognized in TIME's World's Top Health Companies 2025, and Dr. Mansi was named one of TIME Magazine's 100 Most Influential People in AI in 2024, underscoring its impact and innovative standing in the healthcare AI landscape.

Latest updates

Viz.ai Partners with NRHA to Tackle Rural Healthcare AI Adoption Gap

Event summary

  • Viz.ai is collaborating with the National Rural Health Association (NRHA) to improve AI adoption in rural hospitals.
  • Rural hospitals are 25% less likely to adopt AI than urban hospitals due to funding and access constraints.
  • Viz.ai’s platform currently operates in 2,000 hospitals across the United States.
  • The initiative will include educational webinars, case studies, and conference discussions.
  • Viz.ai was the first company to receive CMS reimbursement for AI.

The big picture

Rural healthcare systems face unique challenges – workforce shortages, geographic isolation, and limited resources – that exacerbate disparities in access to care. Viz.ai’s partnership with NRHA represents a targeted effort to address this gap by leveraging AI to improve diagnostic speed and care coordination, a strategy that could unlock a significant, previously untapped market. The initiative also highlights the ongoing need for regulatory support and tailored solutions to drive AI adoption in underserved healthcare settings.

What we're watching

Adoption Rate
The success of this initiative hinges on NRHA’s ability to overcome the systemic barriers hindering AI adoption in rural hospitals, and Viz.ai's ability to tailor its solution to those specific constraints.
Regulatory Impact
Continued CMS reimbursement for AI-driven diagnostics will be crucial for sustaining the program's momentum and encouraging broader adoption across rural healthcare systems.
Market Expansion
Viz.ai's reliance on partnerships like this to expand its reach suggests a strategic pivot towards addressing underserved markets, potentially impacting its growth trajectory beyond its existing urban hospital base.

Viz.ai Partners with J&J to Expand AI-Powered Stroke Care Access

Event summary

  • Viz.ai has entered a commercialization collaboration with Johnson & Johnson to expand access to its Subdural Hemorrhage software solution.
  • The solution utilizes FDA 510(k)-cleared algorithms for automated detection, labeling, and quantification of subdural collections.
  • Viz Assist, an AI-driven chart summarization tool integrated within the platform, aims to accelerate clinical decision-making.
  • The collaboration focuses on identifying patients who may benefit from middle meningeal artery (MMA) embolization for chronic subdural hematoma (cSDH).

The big picture

This partnership reflects the increasing convergence of AI and established medical device players as healthcare providers seek to improve efficiency and patient outcomes. Viz.ai, already recognized for its early CMS reimbursement, is leveraging J&J’s distribution network to expand its reach within the US hospital system. The focus on chronic subdural hematoma and MMA embolization highlights a niche market with potential for growth as novel therapeutic procedures gain traction.

What we're watching

Commercialization
The success of this collaboration hinges on Johnson & Johnson’s ability to effectively integrate Viz.ai’s software into its existing neurovascular offerings and drive adoption within hospitals.
Clinical Adoption
Wider adoption of AI-driven diagnostics will depend on demonstrating tangible improvements in patient outcomes and workflow efficiency, beyond the initial pilot programs.
Regulatory Landscape
Future CMS reimbursement decisions for AI-powered diagnostic tools will significantly influence the financial viability and scalability of Viz.ai’s business model.

Viz.ai Nabs Gold Edison Award, Solidifying Agentic AI Play in Healthcare

Event summary

  • Viz.ai received the Gold Edison Award 2026 for its Viz Hemorrhage solution, marking its fourth Edison Award overall.
  • The Viz Hemorrhage solution combines four FDA-cleared algorithms to identify and characterize hemorrhagic conditions, integrating data, intelligence, and coordination.
  • Viz.ai’s platform is deployed in over 2,000 hospitals across the United States.
  • The company positions itself as a clinical infrastructure layer enabling scalable, agentic workflows across service lines.

The big picture

Viz.ai’s Edison Award reinforces the shift towards integrated AI solutions within healthcare, moving beyond standalone algorithms to encompass entire clinical workflows. The company’s focus on ‘agentic AI infrastructure’ suggests a strategic bet on becoming a foundational layer for hospitals, potentially displacing existing point solutions. This approach, while promising, faces challenges in adoption and integration across diverse hospital systems and workflows.

What we're watching

Market Adoption
The continued expansion of Viz.ai’s platform into additional hospitals will be crucial for sustaining growth and demonstrating the scalability of its agentic AI approach.
Regulatory Scrutiny
Increased regulatory focus on AI in healthcare could impact Viz.ai’s reimbursement models and require ongoing validation of its algorithms' efficacy and safety.
Competitive Landscape
The emergence of competing agentic AI platforms and broader clinical workflow solutions will likely intensify, requiring Viz.ai to continually innovate and differentiate its offerings.

Viz.ai Solidifies AI Leadership as Enterprise Adoption Accelerates

Event summary

  • Viz.ai has been ranked No. 1 in the Black Book Research survey of AI Clinical Decision Support solutions for the second consecutive year.
  • The survey, based on feedback from 1,237 healthcare professionals, evaluated vendors across 18 categories.
  • Viz.ai ranked No. 1 in 13 of those 18 categories.
  • The company's platform is deployed in 2,000 hospitals across the United States.
  • Viz.ai was the first company to receive CMS reimbursement for AI.

The big picture

Viz.ai’s back-to-back No. 1 ranking underscores the accelerating adoption of AI as a core infrastructure layer within healthcare, driven by pressure to improve outcomes and manage operational complexity. The shift towards ‘agentic AI’ platforms, which operationalize insights and connect detection, communication, and action, represents a significant strategic advantage for Viz.ai. This trend is likely to intensify as healthcare providers seek to maximize the return on their AI investments and move beyond isolated tools.

What we're watching

Market Consolidation
The increasing focus on end-to-end clinical impact suggests a potential wave of consolidation within the AI clinical decision support market as smaller, specialized vendors are absorbed by larger platforms.
Reimbursement Risk
Continued reliance on CMS reimbursement for AI services creates a risk if policy changes or stricter evaluation criteria are implemented, potentially impacting Viz.ai’s growth trajectory.
Workflow Integration
The survey highlights the importance of deep integration with existing systems; Viz.ai’s ability to maintain this advantage will be crucial as healthcare organizations increasingly standardize their technology stacks.

Viz.ai Launches Agent Studio, Aiming to Democratize AI Care Pathway Deployment

Event summary

  • Viz.ai launched Viz Agent Studio, a new feature within its Viz One® Platform, allowing health systems to build and deploy custom AI Care Pathways.
  • The platform uses natural language to translate clinical guidelines into workflows, aiming to address persistent gaps in care coordination despite prior AI investments.
  • Viz.ai claims AI Care Pathways can reduce hospital stays (e.g., 3 days in stroke cases), lower readmissions, and accelerate diagnoses.
  • Viz Agent Studio is being deployed across neurology, cardiology, oncology, and pulmonology, with multiple strategic partners.
  • Viz.ai was the first company to receive CMS reimbursement for AI and is ranked #1 in Healthcare AI Platform by Black Book Research.

The big picture

Health systems have struggled to translate AI investments into tangible improvements in care coordination, often due to fragmented workflows and clinician resistance. Viz Agent Studio represents a shift towards empowering clinicians and administrators to directly operationalize clinical guidelines, potentially accelerating the adoption of AI in care delivery. The move also highlights a broader trend of democratizing AI development within healthcare, moving away from centralized, IT-driven solutions.

What we're watching

Adoption Rate
The success of Viz Agent Studio hinges on health systems’ willingness to adopt a self-service AI pathway creation model, which may require significant training and workflow adjustments.
Clinical Validation
While Viz.ai cites internal data, independent validation of the claimed clinical and financial outcomes (reduced length of stay, lower readmissions) will be crucial for broader adoption and reimbursement.
Competitive Landscape
Other AI-driven care coordination platforms may respond with similar self-service capabilities, potentially eroding Viz.ai’s first-mover advantage and driving pricing pressure.

Viz.ai Partners with Alnylam to Expedite Cardiac Amyloidosis Diagnosis

Event summary

  • Viz.ai and Alnylam Pharmaceuticals have partnered to develop an AI Care Pathway for cardiac amyloidosis.
  • The pathway will leverage Viz.ai's FDA-cleared echocardiography AI algorithm (Us2.ai) and generative AI to analyze echocardiograms and coordinate care.
  • Cardiac amyloidosis is a significantly underdiagnosed condition, often resulting in delayed treatment and poor patient outcomes.
  • Viz.ai's platform is deployed in 2,000 hospitals across the US, processing a patient every five seconds.
  • A multi-site pilot study will evaluate the Care Pathway's impact on diagnosis and treatment timelines.

The big picture

The partnership reflects a growing trend of pharmaceutical companies integrating AI-powered diagnostic tools into their care pathways to improve patient outcomes and accelerate treatment. Cardiac amyloidosis represents a significant unmet need, with delayed diagnosis contributing to poor prognosis; this collaboration aims to address this gap by leveraging AI to identify patients earlier. The move also highlights the increasing importance of data-driven approaches in personalized medicine and the potential for AI to transform clinical decision-making.

What we're watching

Clinical Adoption
The success of the pilot study will be critical in determining the broader adoption of the AI Care Pathway within cardiology and heart failure teams, and its impact on clinical workflow.
Reimbursement
While Viz.ai has secured prior CMS reimbursement for AI, the pathway's complexity may require further justification and could influence future reimbursement models for AI-driven diagnostic tools.
Competitive Landscape
Other AI-powered diagnostic platforms are emerging; Viz.ai's ability to demonstrate superior clinical outcomes and integration with Alnylam's therapeutic efforts will be key to maintaining its market position.

Viz.ai Data Suggests AI ECG Screening Could Identify HCM Years Earlier

Event summary

  • Viz.ai presented three studies at ACC.26 demonstrating the effectiveness of its Viz HCM AI-powered ECG analysis solution for detecting hypertrophic cardiomyopathy (HCM).
  • The studies suggest AI-ECG screening can identify previously undiagnosed HCM patients and those lost to follow-up, with one study identifying 11 new HCM diagnoses.
  • One study found that 13% of initially “false positive” AI-ECG results progressed to phenotypic HCM over an average of 2.74 years, prompting a suggestion for repeat echocardiography.
  • Viz.ai has accumulated 15 clinical abstracts supporting its Viz HCM solution, developed in collaboration with Bristol Myers Squibb.
  • The Viz HCM solution is the first FDA-cleared AI algorithm for detecting signs of HCM from a standard 12-lead ECG.

The big picture

The high rate of undiagnosed HCM (85%) represents a significant unmet need and a substantial opportunity for AI-driven diagnostic tools. Viz.ai’s partnership with Bristol Myers Squibb underscores the growing convergence of AI and pharmaceutical innovation in disease management. The demonstrated ability to identify patients earlier could lead to improved outcomes and reduced healthcare costs, but hinges on successful integration into existing clinical workflows and payer reimbursement models.

What we're watching

Workflow Integration
The impact of prospective AI-ECG implementation on clinical workflows and practice patterns remains to be seen, and will be a key factor in adoption rates.
Pre-Positive Cohort
The identification of a “pre-positive” cohort warrants further investigation to determine the optimal timing and frequency of follow-up echocardiography.
Reimbursement Expansion
Viz.ai’s existing CMS reimbursement for AI will likely be a model for broader adoption, but the pace of expansion for AI-driven diagnostic tools will depend on payer acceptance and clinical validation.

Viz.ai Study Shows 44% Stroke Transfer Time Reduction

Event summary

  • A Viz.ai study presented at the International Stroke Conference (ISC) 2026 demonstrated a 44% reduction in door-in-door-out (DIDO) time for stroke patients.
  • The study, led by Caezar G. Jara at Adventist Health + Rideout, evaluated the impact of Viz.ai’s platform, resulting in a DIDO time decrease from 202 minutes to 113 minutes.
  • The reduction was achieved through faster LVO identification, team activation, and streamlined transfer protocols.
  • Viz.ai’s Viz Assist platform, designed for regional and community hospitals, further supports these coordinated workflows.

The big picture

Viz.ai's success underscores the growing recognition of AI's potential to improve patient outcomes and operational efficiency in acute care settings. The 44% reduction in stroke transfer times represents a significant advancement in addressing a critical bottleneck in stroke care pathways, particularly in resource-constrained regional hospitals. This trend is likely to accelerate as healthcare providers seek to leverage technology to meet quality benchmarks and improve patient access to specialized care.

What we're watching

Adoption Rate
The sustainability of these DIDO time reductions will depend on the platform’s adoption rate across a broader range of hospitals and care networks, beyond the pilot program at Adventist Health.
Reimbursement
Continued CMS reimbursement for AI-powered care coordination will be crucial for Viz.ai’s growth and market penetration, especially as competitors enter the space.
Integration
The effectiveness of Viz.ai’s platform hinges on its ability to seamlessly integrate with existing hospital systems and workflows, which could present challenges in larger, more complex organizations.

Viz.ai Appoints CRO to Drive Enterprise Adoption of AI Agent Platform

Event summary

  • Viz.ai appointed Jallel Harrati as Chief Revenue Officer (CRO), effective immediately.
  • Harrati previously served as SVP and GM of New Business Development at Suki.
  • Viz.ai has deployed its platform in 2,000 hospitals across the United States.
  • Viz Assist, Viz.ai’s multimodal AI agent platform, aims to assist clinicians with tasks like chart summaries and coding recommendations.

The big picture

Viz.ai's appointment of a seasoned CRO signals an aggressive push to scale its enterprise AI platform beyond its initial success with AI Care Pathways. The introduction of Viz Assist represents a strategic shift towards a more comprehensive agentic AI solution for healthcare providers, aiming to automate workflows and improve clinical efficiency. This move places Viz.ai in direct competition with other emerging AI-driven clinical solutions providers, highlighting the growing market for AI-powered tools in healthcare.

What we're watching

Execution Risk
Harrati’s success hinges on integrating his experience scaling commercial organizations with Viz.ai’s existing culture and sales processes, particularly given his background at a competitor.
Market Dynamics
The adoption rate of Viz Assist will be a key indicator of whether clinicians find the AI agent platform genuinely valuable and integrates into their workflows, or if it becomes another unused enterprise tool.
Competitive Landscape
The competitive pressure from companies like Suki and others in the AI-driven clinical solutions space will likely intensify as Viz.ai attempts to expand its market share and solidify its position as a category leader.

Viz.ai Integrates Clinical Data with Salesforce Agentforce to Target Pharma Engagement

Event summary

  • Viz.ai and Salesforce have launched a new real-time clinical intelligence service for Salesforce’s Agentforce Life Sciences.
  • The integration connects Viz.ai’s data from nearly 2,000 hospitals (covering 230M lives) to Salesforce’s Agentforce platform.
  • The service aims to power agentic workflows for life sciences companies, enabling targeted education and support for clinicians and patients.
  • Over 110 life science companies have already adopted Agentforce Life Sciences.
  • Viz.ai’s Data 360 connector will be available through the Salesforce AppExchange.

The big picture

The collaboration reflects a growing trend of pharmaceutical companies leveraging real-time data and AI-powered agents to personalize patient engagement and optimize commercial strategies. This move signals a shift away from traditional, volume-based sales models towards value-based care and data-driven decision-making. The integration of Viz.ai’s clinical intelligence with Salesforce’s Agentforce platform represents a significant step towards creating a more connected and responsive healthcare ecosystem.

What we're watching

Adoption Rate
The success of this partnership hinges on the ability of life sciences companies to integrate the new service into existing workflows and demonstrate tangible ROI, which will dictate the pace of broader adoption.
Data Privacy
Given the sensitivity of patient data involved, regulatory scrutiny and compliance challenges will be a key factor in the long-term viability of the offering.
Competitive Response
Other healthcare AI and CRM providers will likely accelerate their own integration efforts, potentially eroding Viz.ai and Salesforce’s first-mover advantage.

Viz.ai Achieves Profitability, Doubles Life Sciences Business Amidst Healthcare AI Adoption

Event summary

  • Viz.ai achieved profitability in its healthcare business in 2025.
  • The company's life sciences business doubled over the past 18 months, adding six new partners.
  • Viz.ai is now deployed in nearly 2,000 hospitals, covering over 230 million lives.
  • New product launches include Viz Oncology and Viz Assist, expanding the platform's functionality.

The big picture

Viz.ai's profitability and expansion into life sciences reflect the broader trend of AI adoption within healthcare and the increasing demand for integrated clinical workflows. The company's ability to combine real-time data with clinician workflows positions it to capitalize on the growing market for AI-powered care coordination, but faces competition from established players and emerging startups. The reliance on strategic partnerships with Salesforce and Microsoft introduces a layer of complexity regarding integration and potential revenue sharing.

What we're watching

Platform Stickiness
The sustained 90% click-through rate on alerts suggests strong clinician engagement, but the long-term impact of integrating with Salesforce and Microsoft on platform stickiness warrants monitoring.
Life Sciences Scale
While the doubling of the life sciences business is encouraging, the overall contribution to revenue and the path to profitability within this segment remain unclear.
Regulatory Landscape
Continued CMS reimbursement for AI-powered solutions is critical for Viz.ai’s growth, and any shifts in regulatory policy could significantly impact adoption rates.

Viz.ai Integrates NCCN Guidelines, Bolstering Oncology AI Platform

Event summary

  • Viz.ai has partnered with the National Comprehensive Cancer Network (NCCN) to integrate NCCN Clinical Practice Guidelines for Breast, Prostate, and Bladder Cancer into its Viz Oncology Platform.
  • The integration aims to provide oncologists with real-time access to evidence-based best practices and identify potential gaps in patient care.
  • The Viz Oncology Suite is a clinical decision support system that aggregates patient data and provides recommendations aligned with NCCN Guidelines.
  • NCCN Guidelines cover over 97% of cancer cases, establishing them as a widely respected standard in oncology.

The big picture

The collaboration reflects a growing trend of integrating AI and clinical guidelines to improve cancer care efficiency and consistency. Viz.ai's move to embed NCCN guidelines directly into its platform positions it to capture a larger share of the expanding clinical decision support market, which is increasingly pressured to demonstrate improved patient outcomes and cost-effectiveness. This partnership also highlights the increasing commoditization of clinical guidelines as a key data asset for AI-driven healthcare solutions.

What we're watching

Adoption Rate
The success of this collaboration hinges on the adoption rate among oncologists; resistance to new workflows or concerns about AI-driven recommendations could limit impact.
Guideline Expansion
Whether Viz.ai will expand the integration to cover additional cancer types and NCCN guidelines will be a key indicator of the platform's long-term value proposition.
Reimbursement
Continued CMS reimbursement for AI-powered clinical decision support will be crucial for Viz.ai's financial sustainability and broader market penetration.

Viz.ai Appoints Oncology Veteran as CMO, Signals Expansion Beyond Stroke

Event summary

  • Viz.ai appointed Dr. Timothy N. Showalter as its first Chief Medical Officer (CMO), effective immediately.
  • Dr. Showalter previously served as CMO at Artera AI, where he led the development of AI-based biomarkers for oncology diagnostics.
  • He founded Advaray, Inc., a radiation therapy device company acquired by CQ Medical.
  • Dr. Showalter will oversee Viz.ai’s clinical strategy and expansion into oncology, pulmonology, and other disease areas.
  • Viz.ai has deployed its platform in over 1,900 hospitals and is trusted by most major life sciences companies.

The big picture

Viz.ai's appointment of Dr. Showalter signals a strategic pivot beyond its initial success in acute stroke care. The company is aiming to leverage its AI platform for broader disease detection and care coordination, a move reflecting the growing demand for AI-powered solutions across various medical specialties. This expansion also highlights the increasing importance of clinical leadership in guiding the development and implementation of AI in healthcare, particularly as regulatory scrutiny and reimbursement pressures intensify.

What we're watching

Product Diversification
Viz.ai's move into oncology and pulmonology represents a significant shift beyond its initial focus on stroke, and success hinges on adapting its AI algorithms and workflows to new clinical contexts.
Clinical Validation
The company's ability to generate robust clinical and financial outcomes data across these new disease areas will be critical for securing broader adoption and justifying reimbursement.
Competitive Landscape
The entry of a seasoned oncology AI executive suggests Viz.ai will face increased competition from established players in the oncology diagnostics space, requiring a differentiated value proposition.
CID: 658